OZEM
Roundhill GLP-1 & Weight Loss ETF
The Roundhill GLP-1 & Weight Loss ETF seeks to provide investment exposure to companies involved in the development and commercialization of GLP-1 therapies and other weight loss solutions.
Global
EQUITY
Active
MANAGEMENT STYLE
$ 50.3 M
ASSETS UNDER MGMT
59 bp
EXPENSES
Fund Basics
| Inception date | May 20, 2024 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| ELI LILLY & CO | 15.7 % |
| NOVO-NORDISK A/S-SPONS ADR | 13.4 % |
| PFIZER INC | 6.3 % |
| CHINA PHARMACEUTICAL GROUP | 5.0 % |
| VIKING THERAPEUTICS, INC. | 4.6 % |
| ZEALAND PHARMA A/S | 4.4 % |
| CHUGAI PHARMACEUTICAL CO LTD | 4.4 % |
| INNOVENT BIOLOGICS, INC. | 4.4 % |
| KAILERA THERAPEUTICS INC | 4.2 % |
| ASCLETIS PHARMA, INC. | 3.9 % |
Constituent Breakdown
| Number of holdings | 21 |
| Herfindahl-Hirschman Index | 690 |
| Wgt avg mkt cap (mns) | $223,196 |
| Large cap (>$10bn) | 66.5% |
| Mid cap ($2-10bn) | 17.7% |
| Small cap (<$2bn) | 7.9% |
| Developed mkts. | 78.4% |
| Emerging mkts. | 12.1% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 41.0 % |
 |
DENMARK | 17.8 % |
 |
HONG KONG | 7.7 % |
 |
JAPAN | 5.7 % |
 |
CHINA | 4.4 % |
 |
CAYMAN ISLANDS | 3.9 % |
 |
SOUTH KOREA | 3.7 % |
 |
BRITAIN | 3.2 % |
 |
SINGAPORE | 0.9 % |
Historical Performance
Standardized Performance (as of 04/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | -9.0% | 23.2% | -- | -- | -- | -- | -- | 11.0% |
| Dividend Yield | 0.0% | 1.5% | -- | -- | -- | -- | -- | 0.8% |
| Total Returns | -9.0% | 24.7% | -- | -- | -- | -- | -- | 11.8% | Ann. Volatility | 24.9% | 25.3% | -- | -- | -- | -- | -- | 25.3% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.90 | 20% |
| MSCI EAFE | 0.93 | 29% |
| MSCI Emg Mkts | 0.53 | 15% |
Liquidity Measures
| Avg. volume (000) | 16 |
| ADV traded (mns) | $1 |
| Turnover | 1.0% |
| Avg. Bid/Ask (% of price) | 0.49% |
Technical Indicators
| 30d moving avg. (EMA) | $31.52 |
| Relative strength (RSI) | 47 |
| MACD/Signal | -0.05/-0.14 |
| Bollinger Bands (Upper/Lower) | $32.58/$30.34 |
| Short interest (% of AUM) | 4.3% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. OZEM |
Expenses vs. OZEM |
ALTAR Score™ vs. OZEM |
|---|---|---|---|---|
| THNR | Amplify Weight Loss Drug & Treatment ETF | 59.5% | 0 bp | +0.3% |
| MEDX | Horizon Kinetics Medical ETF | 28.6% | +26 bp | -4.5% |
| PPH | VanEck Pharmaceutical ETF | 26.9% | -23 bp | +2.0% |
| XLV | Health Care Select Sector SPDR | 23.8% | -51 bp | +1.3% |
| IYH | iShares U.S. Healthcare ETF | 23.3% | -19 bp | +0.5% |
| HRTS | Tema Heart & Health ETF | 22.6% | +16 bp | -2.7% |
| IXJ | iShares Global Healthcare ETF | 20.9% | -17 bp | +1.0% |
| VHT | Vanguard Health Care ETF | 20.9% | -50 bp | -0.3% |
| FHLC | Fidelity MSCI Health Care Index ETF | 20.7% | -51 bp | -0.1% |
| IHE | iShares U.S. Pharmaceuticals ETF | 20.6% | -19 bp | -0.6% |
Risk and Returns: OZEM vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 5/14/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
6.0%
ALTAR SCORE™
75th
PERCENTILE
OVERWEIGHT
ETFRC RATING
There are 585 funds in the Global Equity category with an average
ALTAR Score™ of 4.3% and a standard deviation
of 2.6%. OZEM's ALTAR Score™ is approximately 0.7 standard
deviations above the category average. This places OZEM in the 75th percentile
among funds in the category.
Sell-Side Consensus
$40.82
PRICE TARGET
+28.3%
UPSIDE